This is a working overview of CAS Registry Number, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-26 and is reviewed periodically as new material appears.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
The classic symptom of keratoconus is the perception of multiple "ghost" images, known as monocular polyopia. This effect is most clearly seen with a high contrast field, such as a point of light on a dark background. Instead of seeing just one point, a person with keratoconus sees many images of the point, spread out in a chaotic pattern. This pattern does not typically change from day to day, but over time, it often takes on new forms. People also commonly notice streaking and flaring distortion around light sources. Some even notice the images moving relative to one another in time with their heartbeat. The predominant optical aberration of the eye in keratoconus is coma. The visual distortion experienced by the person comes from two sources, one being the irregular deformation of the surface of the cornea, and the other being scarring that occurs on its exposed highpoints. These factors act to form regions on the cornea that map an image to different locations on the retina. The effect can worsen in low light conditions, as the dark-adapted pupil dilates to expose more of the irregular surface of the cornea. Significant retinal layer thickness reduction is observed in keratoconus, especially in younger patients (<30 years).
== Pathophysiology == Acanthosis nigricans results from activation of growth factor receptor pathways, most commonly insulin-mediated stimulation of insulin-like growth factor receptor on keratinocytes and fibroblasts. Hyperinsulinaemia may also displace IGF-1 from its binding proteins, amplifying epidermal proliferation. Contributing mechanisms include:
In males, testosterone is synthesized primarily in Leydig cells. The number of Leydig cells in turn is regulated by luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In addition, the amount of testosterone produced by existing Leydig cells is under the control of LH, which regulates the expression of 17β-hydroxysteroid dehydrogenase. The amount of testosterone synthesized is regulated by the hypothalamic–pituitary–testicular axis (Figure 2). When testosterone levels are low, gonadotropin-releasing hormone (GnRH) is released by the hypothalamus, which in turn stimulates the pituitary gland to release FSH and LH. These latter two hormones stimulate the testis to synthesize testosterone. Finally, increasing levels of testosterone through a negative feedback loop act on the hypothalamus and pituitary to inhibit the release of GnRH and FSH/LH, respectively. Factors affecting testosterone levels may include:
Flibanserin is the first pharmaceutical product from Sprout Pharmaceuticals for premenopausal women with HSDD. The drug was approved by the FDA in 2015. It compiles a serotonin 5-HT1A receptor agonist and a serotonin 5-HT2A antagonist. and is an antidepressant that was originally developed for depression. This weak partial agonist that acts on dopamine D4 receptors, is also postsynaptic and functions by modulating various neurotransmitters, including dopamine, norepinephrine, and serotonin.
Sources: en.wikipedia.org
The principal chief is the head of the executive branch of the Cherokee National Government, responsible for overseeing an annual budget of over $600 million and more than 3,000 full-time employees. The current principal chief, elected June 1, 2019, is Chuck Hoskin Jr., who formerly held the office of Cherokee Nation secretary of state. The deputy chief acts as the chief in his or her absence. The chief is assisted in managing the executive branch by the secretary of state, the attorney general, the marshal, the treasurer, and several group leaders. The government's functions are divided into several groups, each headed by a group leader. These groups are further divided into several service areas which provide governmental services to the Cherokee people. As of July 2011, there are fifteen groups:
Murex purple was a very important industry in many Phoenician territories and Carthage was no exception. Traces of this once very lucrative industry are still visible in many Punic sites such as Kerkouane, Zouchis, Djerba and even in Carthage itself. According to Pliny, Meninx (today's Djerba) produced the best purple in Africa which was also ranked second only after Tyre's. It was found also at Essaouira (Morocco). The Royal purple or Imperial purple was probably used until the time of Augustine of Hippo (354–430) and before the demise of the Roman Empire.
During a match against Borussia Mönchengladbach in 1996, Wenger presided over Rice's caretaker duties at Arsenal, and ordered the team to switch from their preferred 3–5–2 formation to 4–4–2. The tactical change did not have its desired effect, as Arsenal lost the game having led before Wenger's half-time instruction. For much of the 1996–97 season, Arsenal continued to play 3–5–2 as it was the only formation the defenders were comfortable with, as well as injuries unsettling the side. In Wenger's second season at the club, he reinstated 4–4–2 and focused on strengthening the front six, by signing wingers Overmars and Luís Boa Morte and partnering Vieira with Petit. According to Jonathan Wilson, the system was similar to 4–3–3, as Overmars often pushed higher up the field and Parlour played alongside Vieira and Petit to solidify the midfield. Needing to compensate deficiencies in attack the following season, Wenger relied on his experienced defence to direct games, which conceded 17 goals in 38 league matches. From then on, Wenger deployed an unconventional 4–4–2 with a greater emphasis on attack and movement; his teams between 2001 and 2004 were dominant on the left flank. By the 2005–06 season, clubs in England were increasingly in favour of using the 4–5–1 system. Wenger, having earlier suggested he would never resort to a negative system, later adopted the formation for Champions League matches. The decision to pack the midfield and play a lone striker resulted in Arsenal reaching the final.
Sources: en.wikipedia.org
Meanwhile, workers in the platelet, extracellular matrix, and cell surface fields were also working on multi-subunit receptors. The platelet receptor for fibrinogen contained two glycoprotein subunits termed IIb and IIIa. A monoclonal antibody to a cell surface receptor that blocked cell adhesion to laminin and fibronectin reacted with three distinct subunits in the same molecular weight range as αLβ, αMβ, αXβ, and IIb/IIIa. Proteins with high molecular weight, sharing a common subunit, were identified on lymphocytes and non-hematopoietic cells. After the discovery that an RGD motif in fibronectin is sufficient for recognition by its receptor and common to other extracellular proteins, the fibronectin and vitronectin receptors were isolated and their sequences determined and platelet protein IIb/IIIa was also shown to recognize RGD. Sequences of these receptors showed that their alpha subunit sequences were homologous to one another and to those earlier reported for LFA-1 (αLβ) and Mac-1 (αMβ). A large number of other papers appeared in 1986-1987 reporting further sequences and relationships among these receptors, including from the Springer lab on the β-subunit shared by LFA-1 (αLβ), Mac-1 (αMβ), and αXβ. Richard Hynes chaired the 1987 Gordon Research Conference on Fibronectin. Hynes had worked on fibronectin, and in 1986 his group isolated a cDNA encoding a subunit recognized by an antibody to the laminin and fibronectin receptors, which he named integrin.
F-ATPase gene linkage and gene order are widely conserved across ancient prokaryote lineages, implying that this system already existed at a date before the last universal common ancestor, the LUCA. Nick Lane: The Vital Question: Energy, Evolution, and the Origins of Complex Life, Ww Norton, 2015-07-20, ISBN 978-0393088816 (Link points to Figure 10 showing model of ATP synthase) Boris A. Feniouk: "ATP synthase — a splendid molecular machine" Well illustrated ATP synthase lecture Archived 2008-12-02 at the Wayback Machine by Antony Crofts of the University of Illinois at Urbana–Champaign. Proton and Sodium translocating F-type, V-type and A-type ATPases in OPM database The Nobel Prize in Chemistry 1997 to Paul D. Boyer and John E. Walker for the enzymatic mechanism of synthesis of ATP; and to Jens C. Skou, for discovery of an ion-transporting enzyme, Na+, K+-ATPase. Harvard Multimedia Production Site — Videos – ATP synthesis animation David Goodsell: "ATP Synthase- Molecule of the Month" Archived 2015-09-05 at the Wayback Machine
The structure of CARD11 involves multiple domains that impact the protein's ability to activate BCL10 and NF-κB activity. CARD11 has a CARD domain, a serine-threonine rich region, is associated with the N-terminus, which is essential for NF-κB signaling activity. The region following the CARD domain is highly coiled. In deleting the CARD domain, all NF-κB signaling activity was prevented. The CARD domain on CARD11 interacts with the CARD domain on BCL10 to initiate the signaling pathway. On the C-terminus of CARD11 there is the MAGUK domain that is associated with the cell membrane. This domain is often referred to as the inhibitory domain. Protein kinase C activates CARD11 by phosphorylating serine residues within the inhibitory domain. CARD11 has been shown to interact with BCL10. This interaction occurs between the CARD domain on BCL10 and the CARD domain on CARD11, and results in signal propagation and NF-κB activation. Human CARD11 genome location and CARD11 gene details page in the UCSC Genome Browser.
In vitro testing suggests that unidentified wolfberry phytochemicals in goji tea may inhibit metabolism of medications, such as those processed by the cytochrome P450 liver enzymes, including such drugs as warfarin. Organochlorine pesticides are conventionally used in commercial wolfberry cultivation to mitigate infestation by insects. China's Green Food Standard, administered by the Chinese Ministry of Agriculture's China Green Food Development Center, permits some pesticide and herbicide use. Agriculture in the Tibetan Plateau (where many "Himalayan" or "Tibetan"-branded berries supposedly originate) conventionally uses fertilizers and pesticides, making organic claims for berries originating there dubious. Since the early 21st century, high levels of insecticide residues (including fenvalerate, cypermethrin, and acetamiprid) and fungicide residues (such as triadimenol and isoprothiolane), have been detected by the United States Food and Drug Administration in some imported wolfberries and wolfberry products of Chinese origin, leading to the seizure of these products.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.